Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two CasesKristin Gerhardt, Vladan Vučinić, Madlen Jentzsch et al.|Frontiers in Oncology|2021Cited by 6
The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell ResolutionDavid Fandrei, Maximilian Merz, Markus Kreuz et al.|Blood|2024Cited by 4
Rapid Response to Idecabtagene Vicleucel in a Myeloma Patient Refractory to Multiple Prior Lines of Anti-BCMA Directed TherapiesMaximilian Merz, Uwe Platzbecker, Vladan Vučinić et al.|Blood|2022Cited by 1
Cellular dynamics and their impact on outcome in patients with mantle cell lymphoma during treatment with chimeric antigen receptor (CAR) T cellsR. Weiß, Vladan Vučinić, C. P. Fernandez et al.|Hematological Oncology|2023Cited by 0
P1415: CELLULAR DYNAMICS IN RESPONDERS AND NON-RESPONDERS AFTER THE TREATMENT OF PATIENTS WITH AGGRESSIVE B-ZELL LYMPHOMAS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLSThomas Georgi, Vladan Vučinić, Carmen Fernandez-Perez et al.|HemaSphere|2023Cited by 0